Thiazole derivative and applications thereof
Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.
1. A compound represented by formula (I), or an isomer or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is selected from H, C 1-4 alkyl or C 3-6 cycloalkyl;
R 2 and R 3 are independently selected from H, or are independently selected from C 1-3 alkyl optionally substituted by 1, 2 or 3 R;
R 4 , R 5 , and R 6 are independently selected from H, F, Cl, Br or I, or are independently selected from the group consisting of phenyl, 5- to 6-membered heteroaryl, and 5- to 6-membered heteroaryl-O—, each of which is optionally substituted by 1, 2 or 3 R;
ring A is selected from C 5-7 cycloalkyl or 5- to 8-membered heterocycloalkyl;
R is selected from F, Cl, OH, NH 2 , —COOH, C 1-3 alkyl, C 1-3 alkoxy, —N,N-di(C 1-3 alkyl)amino, or C 1-3 alkyl-C(═O)O—;
the heteroatom or heteroatom group in the 5- to 6-membered heteroaryl and the 5- to 8-membered heterocycloalkyl is independently selected from —S—, —O—, —NH—, or N; and
in any of the above cases, the number of the heteroatom or heteroatom group is independently selected from 1, 2 or 3.
2. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R is selected from F, Cl, OH, NH 2 , —COOH, CH 3 ,
or CH 3 —C(═O)O—.
3. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is selected from H or
4. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 and R 3 are independently selected from H, or are independently selected from the group consisting of CH 3 and —CH 2 —CH 3 , each of which is optionally substituted by 1, 2 or 3 R.
5. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 2 and R 3 are independently selected from H, CH 3 , —CH 2 —OH, or —CH 2 —OAc.
6. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 5 , wherein R 2 is selected from H, CH 3 , —CH 2 —OH, or —CH 2 —OAc.
7. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 5 , wherein R 3 is selected from H or CH 3 .
8. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 4 , R 5 and R 6 are independently selected from H, F, Cl, Br or I, or are independently selected from the group consisting of pyridyl, thiazolyl, and pyridyl-O—, each of which is optionally substituted by 1, 2 or 3 R.
9. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 7 , wherein R 4 , R 5 and R 6 are independently selected from H, F, Cl, Br or I, or are independently selected from the group consisting of
each of which is optionally substituted by 1, 2 or 3 R.
10. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 9 , wherein R 4 , R 5 , and R 6 are independently selected from H, F, Cl,
11. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 10 , wherein R 4 is selected from H, F, Cl, or
12. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 10 , wherein R 5 is selected from H,
13. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 10 , wherein R 6 is selected from H, F, Cl, or
14. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein ring A is selected from piperidyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, oxepanyl, cyclopentyl, or cyclohexyl.
15. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the moiety
is selected from:
16. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 15 , wherein the moiety
is selected from:
17. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 16 , wherein the moiety
is selected from:
18. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 1 , which is selected from:
wherein
R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined in claim 1 .
19. A compound of a formula, or an isomer or a pharmaceutically acceptable salt thereof, wherein the formula is selected from the group consisting of
20. The compound, or the isomer or the pharmaceutically acceptable salt thereof according to claim 19 , which is selected from:
21. A pharmaceutical composition, comprising:
a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 , and
a pharmaceutically acceptable carrier.